Precision treatment for HR+ HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a personalized treatment plan for people with advanced HR+ HER2- breast cancer whose cancer has progressed on a CDK4/6 inhibitor. It uses a special molecular test to match you to the targeted therapy most likely to work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have HR-positive, HER2-negative breast cancer that has spread or come back (advanced stage).
- Your tumor must have a specific molecular subtype (SNF1 or SNF3) as determined by a digital pathology test.
- Your cancer has worsened while taking a CDK4/6 inhibitor (like Ibrance) or within 12 months after finishing it.
- You have not had more than one line of treatment for metastatic disease, and no chemotherapy for metastatic disease.
- You are able to take oral medications and have adequate organ function (blood counts, liver, kidney).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
This trial tests whether the drug fluzoparib (a type of PARP inhibitor) can help prevent breast cancer from coming back after surgery. It is for people who have specific changes in their genes (called germline HRR mutations) and who had a high risk of recurrence based on their tumor type and response to earlier treatment.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.